Effective gene delivery to the central nervous system (CNS) is vital for development of novel gene therapies for neurological diseases. Adeno-associated virus (AAV) vectors have emerged as an effective platform for in vivo gene transfer, but overall neuronal transduction efficiency of vectors derived from naturally occurring AAV capsids after systemic administration is relatively low. Here, we investigated the possibility of improving CNS transduction of existing AAV capsids by genetically fusing peptides to the N-terminus of VP2 capsid protein.
Effective gene delivery to the central nervous system (CNS) is vital for development of novel gene therapies for neurological diseases. Adeno-associated virus (AAV) vectors have emerged as an effective platform for in vivo gene transfer, but overall neuronal transduction efficiency of vectors derived from naturally occurring AAV capsids after systemic administration is relatively low. Here, we investigated the possibility of improving CNS transduction of existing AAV capsids by genetically fusing peptides to the N-terminus of VP2 capsid protein.
A novel vector AAV-AS, generated by the insertion of a poly-alanine peptide, is capable of extensive gene transfer throughout the CNS after systemic administration in adult mice. AAV-AS is 6-and 15-fold more efficient than AAV9 in spinal cord and cerebrum, respectively. The neuronal transduction profile varies across brain regions but is particularly high in the striatum where AAV-AS transduces 36% of striatal neurons. Widespread neuronal gene transfer was also documented in cat brain and spinal cord. A single intravenous injection of an AAV-AS vector encoding an artificial microRNA targeting huntingtin (Htt) resulted in 33-50% knockdown of Htt across multiple CNS structures in adult mice. This novel AAV-AS vector is a promising platform to develop new gene therapies for neurodegenerative disorders.
INTRODUCTION
Recombinant AAV vectors have emerged as the vehicle of choice for in vivo gene transfer to the central nervous system (CNS) due to efficient transduction of neurons 1 and other cell types of therapeutic relevance. [2] [3] [4] AAV vectors are nonpathogenic and have a relatively low immunogenic and cytotoxicity profile, and importantly have been shown to direct stable long-term transgene expression in the brain of large animal models 5, 6 and humans. 7, 8 The first generation of AAV gene therapy for neurological diseases is based on intracranial injections into target structures and has proven effective in numerous mouse and large animal models of neurodegenerative diseases. 6, 9 The efficacy of intraparenchymal infusion of AAV vectors for CNS gene therapy has improved through the identification of new AAV capsids with better transduction and distribution properties, [10] [11] [12] as well as the use of convection-enhanced delivery techniques 13 and magnetic resonance imaging-guided infusion. 14 Several clinical trials have been conducted or are currently underway to test intracranial injection of AAV vectors for different neurodegenerative diseases. 7, 8, [15] [16] [17] [18] There is an increasing recognition that many neurodegenerative diseases affect more than a single structure in the CNS and dominant phenotypic manifestations driven by a particular structure may be a reflection of different kinetics of disease progression across neuronal populations. Therapeutic efficacy in these disorders will therefore depend heavily on efficiently targeting all structures involved in disease pathophysiology. Huntington's disease (HD) is an example of an evolving perspective on target structures for therapeutic intervention. A recent study using transgenic HD mice showed that combined deletion of mutant huntingtin (Htt) in cortical and striatal neurons is necessary to ameliorate all behavioral deficits and neurodegeneration, while deletion in each population individually resulted only in partial effects. 19 The implication is that transformative clinical outcomes in a disease such as HD may only be achieved when therapeutic interventions are effective across multiple brain structures. The same case could be made for numerous other neurodegenerative diseases with diverse neuropathological features. Achieving global gene transfer to the CNS using intraparenchymal injections is a daunting, perhaps impossible task, especially considering the complex geometry and volume of the cortices. Transport of AAV vectors from the injection site to axonally connected structures can expand the therapeutic reach of local interventions, [20] [21] [22] [23] but massive doses may be needed to achieve significant transduction and coverage in distal structures.
The discovery that AAV9 can cross the blood-brain barrier (BBB) after intravascular delivery in neonatal and adult animals was a critical step for AAV-based CNS gene therapy. 24 Other AAV capsids such as AAVrh8 and AAVrh10 were subsequently shown to share this property. 25, 26 Several studies have demonstrated the therapeutic efficacy of intravenously delivered AAV9 vectors in animal models of spinal cord motor neuron degeneration 27, 28 and neurometabolic disorders. [29] [30] [31] However, while intravascular infusion of AAV9 is efficient for gene delivery to spinal cord motor neurons, 24, 26 dorsal root ganglia, 32 and enteric nervous system neurons, 33, 34 the vast majority of transduced cells in the brain are either glia or endothelial cells with sparse neuronal transduction. 24, 25 The tropism of AAV9 to spinal cord motor neurons, which is consistent across species, 24, 32, 35 contributed to the phenotypic rescue of spinal muscular atrophy mice treated at postnatal day 2 (PND2) by systemic infusion of an AAV9 vector encoding survival motor neuron (SMN) protein. 27 However, the effectiveness of AAV9-SMN treatment declined rapidly with age and infusion at PND5 showed only a modest survival benefit and no effect by PND10. 27 The reduced therapeutic benefit with age correlated with declining transduction of spinal cord motor neurons at older ages when most transduced cells were glia. 27 While systemic delivery of AAV9 vectors has proven exceptionally efficient in mouse models of Canavan disease treated as late as PND20 31 and in adult models of lysosomal storage diseases, 29, 30 therapeutic efficacy in these diseases is likely less dependent on neuronal transduction. In Canavan disease, it is possible that any transduced cell overexpressing aspartoacylase may function as a metabolic sink for N-acetyl aspartic acid. 31 In lysosomal storage disorders, there is a cross correction mechanism in which AAV-transduced cells secrete large quantities of functional enzyme that is taken up and correctly targeted to the lysosomes of enzyme-deficient cells.
Therefore, disperse N-acetyl aspartic acid metabolic sinks or sources of functional lysosomal enzymes throughout the CNS, regardless of phenotype, are likely to exert a powerful therapeutic effect. Most neurological diseases, however, are unlikely to benefit from such mechanisms and will require efficient neuronal gene transfer to change the course of disease progression. There is therefore a clear need for AAV capsids with improved neuronal transduction properties to develop the next generation of gene therapies for multifocal neurodegenerative diseases. AAV capsids with novel or enhanced properties have been developed through directed evolution, [36] [37] [38] [39] mutational scanning 40 and display of targeting peptides on AAV capsids. [41] [42] [43] Here, we investigated whether incorporating additional targeting modules through insertion of different peptides into the capsid of an AAV9 variant would increase CNS gene transfer efficiency.
RESULTS

Insertion of poly-alanine peptide in AAV9.47 capsid enhances neuronal gene transfer in adult mice
We chose AAV9.47 as the capsid in which to test our peptidegrafting approach as this quadruple mutant of AAV9 (S414N, G453D, K557E, T582I) has comparable CNS gene transfer properties to AAV9 but decreased tropism to liver 44 Figure S1 ). Peptides were grafted on the AAV9.47 capsid surface via genetic fusion to the N-terminus of VP2 using a previously described approach 45 (Figure 1a ). Unexpectedly, one of the control vectors used for this screen, a peptide-modified AAV9.47 vector carrying a string of 19 alanines in the VP2 capsid protein, designated as AAV-AS (Figure 1b) , showed a remarkable increase in CNS transduction efficiency compared to AAV9 (Figure 2a ) after systemic delivery in 6-8-week-old C57BL/6 mice (Figure 2a ). AAV-AS vector transduced diverse neuronal populations, glia and endothelia throughout the brain and spinal cord, including extensive transduction of neurons in motor cortex and striatum (Figure 2b) . We also observed efficient transduction of granule cells in the dentate gyrus as well as motor neurons and interneurons in the spinal cord (Figure 2b) . The identity of GFP-positive cells with neuronal morphology in cortex, striatum, and spinal cord was confirmed (Figure 2c) . GFP-positive neurons in the striatum were shown to be DARPP32-positive medium spiny neurons (Figure 2c) . Neuronal transduction was apparent in many brain regions of AAV-AS-injected mice with the exception of thalamus and hypothalamus where only sparse transduction was observed (Supplementary Figure S2) . AAV-AS also transduced glial fibrillary acidic protein (GFAP)positive astrocytes (Figure 2c) , oligodendrocytes in the corpus callosum and Bergmann glia in the cerebellum (Supplementary Figure S2) . The transduction profile of AAV9 was limited to glial cells and endothelia in most CNS regions analyzed (Figure 2b and Supplementary Figure S2 ). Western blot analysis of AAV preparations confirmed incorporation of the chimeric poly-alanine VP2 protein in the AAV-AS capsid (Figure 3a) . Quantification of GFP-positive neurons revealed AAV-AS transduced as many as 36% of striatal neurons compared to only 0.45% by AAV9. In contrast, the increase in transduced thalamic neurons was more modest (Figure 3b) . The CNS transduction efficiency of AAV-AS vector was also reflected in its biodistribution profile. More vector genomes were found in (Figure 3c) . These findings were corroborated by comparable increase in GFP protein in cerebrum and spinal cord (Figure 3d) . The increased gene transfer efficiency for AAV-AS vector compared to AAV9 appears to be restricted to CNS, as transduction of liver, muscle, lung, pancreas, and kidney was identical for both AAV vectors based on analysis of vector genome content (Figure 3e and Supplementary Figure S3 ) and GFP protein levels (Figure 3f) . No inflammatory response characterized by reactive astrogliosis or microgliosis was observed due to AAV-AS infusion (Supplementary Figure S4) .
(Supplementary
As a first step to understand how the poly-alanine peptide enhances CNS transduction of AAV9.47, we carried out a cell culture study to determine whether it changes the capsid interaction with exposed galactose residues on cell surface glycans. Terminal N-linked galactose is the primary cell surface receptor for AAV9. 46, 47 Binding studies in parental (Pro5) and sialic acid-deficient (Lec2) CHO cells showed no difference in receptor preference between AAV-AS, AAV9.47, and AAV9 vectors (Supplementary Figure S5) .
AAV-AS transduces neurons throughout the cat brain after systemic administration
Next we assessed whether the neuronal transduction properties of AAV-AS are reproducible in cats as there are numerous models of neurodegenerative diseases in this species. Consistent with results in mice, AAV-AS transduced diverse neuronal populations across the cat brain and spinal cord, including neurons in cerebral cortex, striatum and reticular formation, Purkinje neurons in cerebellum and motor neurons in the oculomotor nucleus located in ventral midbrain, spinal nucleus of the trigeminal nerve in brainstem and throughout the spinal cord (Figure 4a,b) . Curiously, no endothelial and only sparse glial transduction was apparent in the cat brain in this study.
Widespread knockdown of Htt in CNS after systemic delivery of AAV-AS vector
Finally, we evaluated the therapeutic potential of AAV-AS vector for Huntington's disease, a fatal autosomal dominant neurodegenerative disease caused by expansion of a CAG repeat in the 48 Currently, there is no treatment for this devastating disease, but experimental RNAi 49, 50 and oligonucleotide 51 therapies have shown promising results. AAV-AS and AAV9 vectors encoding GFP and an U6-driven artificial microRNA specific for mouse Htt (miR Htt ) were infused systemically in C57BL/6 mice. The knockdown efficiency of this AAV-miR Htt construct was 93% in a transient transfection assay in cell culture (Supplementary Figure S6) . Huntingtin mRNA and protein levels in CNS and liver were assessed at 4 weeks postinjection (Figure 5 ). AAV-AS vector resulted in 33-50% reduction in Htt mRNA in striatum, motor cortex, and spinal cord, and was better than AAV9 in all brain regions, but comparable in the spinal cord (Figure 5a) . Conversely, AAV-AS was less potent than AAV9 in lowering Htt mRNA in liver (Figure 5a) . Western blot analysis of Htt protein levels corroborated the differences between AAV9 and AAV-AS in the striatum, motor cortex and thalamus as well as in liver (Figure 5b) . As anticipated, the reduction in Htt protein levels was inversely proportional to GFP protein levels, which indicates that higher CNS transduction efficiency leads to greater reduction in huntingtin mRNA and protein.
DISCUSSION
The enhanced CNS transduction properties of AAV-AS represent an important improvement from AAV9 toward the ultimate goal of achieving gene transfer to the majority of cells in the CNS, particularly neurons. The neuronal transduction efficiency of recently discovered capsids capable of crossing the adult BBB (such as AAVrh8 and AAVrh10) is not quantitatively higher than AAV9. 25 In contrast, the new AAV-AS vector described here is more efficient than AAV9 at transducing neurons in striatum and cerebral cortex. In addition, transduced motor neurons are evident in the spinal cord of AAV-AS injected mice, in contrast to AAV9 used in these experiments and in prior work. 24 Nonetheless, the CNS transduction profile of AAV9 in this study appears less robust than in previous publications, 25, 52 possibly due to the lower dose and the relatively weak intron-less promoter used in this study. While we are unable to completely exclude the possibility that the potency of our AAV9 vector is lower than those from other laboratories, we believe this is unlikely a major factor in the results reported here because the AAV vectors were prepared by the same method and titers determined in the same qPCR reaction to ensure that animals received comparable doses of the two vectors. Moreover, the CNS neuronal transduction profile of AAV-AS was also reproduced in a normal cat, although some differences such as the absence of transduced endothelium were apparent, which could be the result of variability in promoter efficiency across species. An important aspect to consider is that the widespread neuronal transduction profile of AAV-AS was achieved with a dose (5 × 10 11 vg/mouse) approximately 8-10-fold lower than in previous studies characterizing the CNS tropism of AAV9 24 and other natural AAV capsids 25 in adult mice. The extent of striatal neuronal transduction far exceeds any previous publication with systemic delivery of any AAV capsid, regardless of dose. Nonetheless, it is important to note the neuronal transduction properties of this new AAV-AS capsid are not uniform across the brain as evidenced by the considerable difference in percentage of GFP-positive neurons between striatum and thalamus.
The variability in neuronal transduction with AAV-AS in different brain structures is likely to be determined by the CNS distribution of cell surface receptor(s) used by this new AAV vector to cross the BBB and transduce neurons. Glycans with terminal galactose have been identified as the primary factor for AAV9 attachment to the cell surface 46, 47 and the galactose-binding domain on the AAV9 capsid surface has been identified. 53 Integrin binding appears to have a role in AAV9 transduction. 54 Nonetheless, the mechanism that AAV9 and other AAV capsids use to cross the BBB, or cerebrospinal fluid-blood barrier as previously suggested 26 is presently unknown. To our knowledge, there is no evidence suggesting that poly-alanine peptides target the CNS after vascular infusion, or are present in proteins such as transferrin or insulin that are known to cross the brain through transcytosis. The topological location of the N-terminus of AAV VP2 is uncertain since there is no crystallographic information on the location of VP1 or VP2 proteins for any of the AAV capsids with characterized structures. 55, 56 A recent study, however, indicates that the N-terminus of chimeric VP2 proteins is exposed on the capsid surface of at least 70% of capsids, 43 suggesting this may also be the case for the poly-alanine peptide in AAV-AS. The results from our study on CHO cells show that cell surface binding of AAV-AS is identical to AAV9 and AAV9.47, suggesting the interaction with glycans with exposed terminal galactose residues is not affected by the poly-alanine peptide. The impact of the poly-alanine residues, however, on the interaction of AAV9.47 capsid with co-receptors on the luminal surface of brain microvascular endothelial cells or other cells along the BBB and cerebrospinal fluid-blood barrier is presently unknown. Further studies will be necessary to uncover the mechanism that underlies this increased efficiency.
The potential of AAV-AS for development of potent therapies for neurological diseases is apparent by its efficacy in reducing huntingtin (Htt) mRNA by 40-50% in striatum and motor cortex-two structures relevant to HD pathophysiology-after a single systemic infusion. Earlier studies investigating direct striatal injection of AAV vectors encoding Htt-specific shRNA or microRNAs in adult mice have consistently reported no higher than 40-60% silencing of Htt mRNA at the injection site. 49, 50, 57 A recent study investigating the therapeutic efficacy of a systemically delivered AAV9-miR vector in HD mouse models was unable to demonstrate Htt mRNA knockdown in the brain of transgenic BACHD mice, and 33% mRNA knockdown in the striatum but no significant difference in the frontal cortex of N171-82Q mice upon administration of a higher dose, 58 which agrees well with the extent of knockdown documented in this study with AAV9 vector.
There is an apparent discrepancy between the differential in GFP transduction efficiency of striatal neurons between AAV-AS and AAV9 vectors (36% versus <1 %) and the comparatively modest increase in Htt knockdown in the same structure with AAV-miR Htt vectors. It is key to note that knockdown is a sum effect of all transduced cells in a particular structure, and not just the neuronal population. This is exemplified by the comparatively smaller 6-15-fold increase in AAV-AS transduction compared to AAV9 when measured by vector genome quantification, where the contribution of every transduced CNS cell is taken into account. This could indicate that AAV9 transduces other cell types to some extent, but the resulting GFP expression level from the CBA promoter used in this study is below the detection limit of our immunohistochemical staining. By the same measure, it is possible the degree of enhancement of neuronal transduction between the two vectors may not be as large as suggested by the histological quantification results. Importantly, as mentioned above, AAVmediated Htt silencing in the striatum after direct injection has been reported at a maximum of 40-60%, even at the site of local injection where the percentage of transduced cells is very high. The reasons for this maximum effect are unknown at the moment, but could be due to only a fraction of Htt mRNA in CNS cells being accessible to the RNAi pathway. Therefore, the 33-50% reduction documented by systemic infusion of AAV-AS is likely to be near or at the maximum Htt silencing possible with AAV vectors engaging the RNAi pathway in the brain, irrespective of any further gene transfer efficacy. The use of differing promoters and vector doses further confounds drawing any direct quantitative correlation between the two experiments.
The reduction in Htt mRNA across the brain achieved with AAV-AS makes it a promising new platform for development of a global gene therapy approach for Huntington's disease as well as other neurological diseases affecting broadly distributed neuronal populations, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia and Rett syndrome, among others. In conclusion, AAV-AS is the first AAV capsid with superior CNS gene transfer properties since the discovery of AAV9 and provides a potent new platform for development of novel gene therapies for neurological diseases.
MATERIALS AND METHODS
Generation of packaging constructs. AAV9.47 trans packaging plasmid was generated by replacing a portion of the AAV9 cap sequence in packaging plasmid pAR-9 with a de novo synthesized fragment carrying the following mutations S414N, G453D, K557E and T582I described in the original work 44 (GenScript USA, Piscataway, NJ) (amino acid numbering beginning at VP1) using In-Fusion cloning kit (Clontech Laboratories, Mountain View, CA). Packaging plasmid necessary to express either only VP1 and VP3 capsid proteins, or VP2 protein fused to peptide were generated by introducing point mutations (T138A substitution to generate VP1,3 plasmids; M1L for VP2 plasmids) as described for AAV2. 45 Peptide and linker (G 4 S) coding sequences were cloned at the N-terminus of VP2 using In-Fusion cloning kit to generate peptide-VP2 expression plasmids.
Vector particle production, titer quantification, and quality analysis.
The self-complementary AAV-CBA-GFP vector used in these studies carries an expression cassette comprised of the CBA promoter without an intron to drive expression of GFP and a rabbit β-globin poly-adenylation signal. 26 Sequences targeting mouse Htt mRNA were embedded into the artificial miR-155 scaffold to generate the following cassette: 5′-ctggag gcttgctgaaggctgtatgctgTTTAGACTTGTGTCCTTGACCTgttttggccactg actgacTGGCAAAGCACAAGTCTAAAcaggacacaaggcctgttactagcactcac atggaacaaatggcc-3′ (targeting sequence in bold uppercase). This artificial miRNA targets position 1090 in exon 8 of mouse huntingtin gene. eGFP and artificial miRNA cassette were expressed under the control of the cytomegalovirus enhancer/chicken β-actin promoter containing the β-actin exon and chimeric intron.
To generate peptide-grafted AAV vectors, 293T cells were cotransfected with the following mix of plasmids using the calcium phosphate precipitation method: 7.96 μg transgene plasmid, 25.6 μg adenoviral helper plasmid pFΔ6, and a 5:1 ratio of VP1,3 packaging plasmid and peptide-VP2 packaging fused expression plasmid in trans, for a total amount of 12.2 μg, per 2.1 × 10 7 cells plated. Seventy-two hours post-transfection, cells were harvested and cell lysates prepared by three cycles of freeze-thaw and treated with Benzonase (Sigma-Aldrich, St. Louis, MO) (50 U/ml cell lysate, 37 °C, 30 minutes). rAAV was purified from cell lysates by iodixanol density-gradient ultracentrifugation 59 (Optiprep density gradient medium, Axis-Shield, Oslo, Norway). Residual iodixanol was removed by replacing with Buffer B (20 mmol/l TRIS, 0.5 M NaCl, pH 8.5) using a 100 kilodalton (kDa) cutoff centrifugation device (Amicon Ultra-15, Merck Millipore, Cork, Ireland) by three rounds of centrifugation at 1,500× g and dialyzed twice using a 10,000 molecular weight cutoff dialysis cassette (Slide-A-Lyzer, Thermo Scientific, Rockford, IL) against a 1,000-fold volume of phosphate buffer saline (PBS) for >2 hours and once overnight at 4 °C. After treatment of stocks with DNase I (Roche Diagnostics GmbH, Mannheim, Germany, 2 U/μl vector, 37 °C, 30 minutes), the titer of rAAV vectors was determined by real-time quantitative PCR (qPCR) using probe and primers specific for the rabbit β-globin polyA sequence (Integrated DNA Technologies, Coralville, IA). For stoichiometric analysis of capsid proteins, 1 × 10 10 vector particles of purified vector were subjected to western blotting by standard SDS-PAGE technique. AAV capsid proteins were detected using mouse monoclonal anti-AAV capsid protein antibody clone B1 (1:500, American Research Products, Waltham, MA, 03-65158), peroxidase-linked anti-mouse secondary antibody (1:2,000, GE Healthcare UK, Buckinghamshire, UK, 380199) and ECL Western Blotting Substrate (Pierce Protein Research Products, Rockford, IL).
Vector administration and tissue processing. The Institutional Animal
Care and Use Committees at the University of Massachusetts Medical School and Auburn University reviewed and approved all experiments in mice and cats, respectively, in compliance with guidelines from the National Institutes of Health (Bethesda, MD).
rAAV vectors were administered via the tail vein in a volume of 200 μl into 6-8-week-old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME). A dose of 5 × 10 11 vg/mouse was administered for immunochemical studies and biodistribution analysis.
For immunochemical and GFP fluorescence studies, mice were trans-cardially perfused at 4 weeks postinjection first with ice cold 1× PBS, followed by 4% paraformaldehyde solution (Fisher Scientific, Fair Lawn, NJ). Tissues were harvested and postfixed in 4% paraformaldehyde solution at 4 °C for an additional 24 hours. Postfixed tissues were transferred to 30% sucrose in 1× PBS for cryoprotection. Tissues were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, CA) and frozen in a dry-ice-isopentane bath and stored at −80 °C.
For biodistribution analysis, mice were trans-cardially perfused at 4 weeks postinfusion with ice-cold 1× PBS. Tissues were harvested immediately, frozen on dry ice and stored at −80 °C.
Cat studies. rAAV vector was packaged by University of Massachusetts
Medical School Viral Vector Core by transient transfection followed by purification by cesium chloride sedimentation, 60, 61 and administered through the carotid artery into a 2-month-old normal domestic short haired cat at a dose of 1.29 × 10 13 vg. The cat was not screened for pre-existing anticapsid neutralizing antibodies. At 4 weeks postinfusion, the injected cat was trans-cardially perfused with cold 1× PBS. Various tissues were harvested and fixed in 4% paraformaldehyde in PBS at 4 °C. The brain was cut into 0.6 cm coronal blocks prior to immersion in fixative. Processing of postfixed brains and spinal cords for immunohistochemical (IHC) and immunofluorescence studies was identical to that for mouse studies.
Immunohistochemical detection of GFP expression.
For chromogenic IHC, 40 μm serial sections of brains and 30 μm serial sections of spinal cord were incubated for 96 hours in anti-GFP primary antibody (ABfinity rabbit monoclonal anti-GFP 1:1,000, G10362, Life Technologies, Grand Island, NY), or overnight in anti-GFAP (rabbit polyclonal anti-GFAP 1:500, Z0334, Dako, Glostrup, Denmark) or anti-Iba1 (rabbit polyclonal anti-Iba1 1:1,000, 019-19741, Wako, Osaka, Japan) at 4 °C. After washing with 1× PBS, sections were incubated in appropriate biotinylated secondary antibody (biotinylated anti-rabbit antibody, Vector Laboratories, Burlingame, CA), followed by incubation in ABC reagent (PK-6100, Vector Laboratories). Sections were developed with 3,3′-diaminobenzidine reagent (DAB) according to the manufacturer's instructions (SK-4100, Vector Laboratories), dehydrated with increasing concentrations of ethanol, cleared with xylene and mounted using Permount mounting medium (Fisher Scientific).
For immunofluorescence studies, 40 μm sections of brains and 30 μm sections of spinal cord were incubated for 24 hours in a cocktail of appropriate primary antibodies at 4 °C. The primary antibodies used were: rabbit polyclonal anti-GFP (1:1,000, Life Technologies, Grand Island, NY, A11122), mouse monoclonal anti-NeuN (1:500, EMD Millipore, Billerica, MA, MAB377), mouse monoclonal anti-DARPP32 (1:250, BD Biosciences, Franklin Lakes, NJ, 611520), mouse monoclonal anti-GFAP (1:500, Abcam, Cambridge, MA, ab4648). After washing in 1× PBS, sections were incubated for 1 hour at room temperature in appropriate secondary antibodies, washed in 1× PBS and mounted using Permafluor mounting media (Thermo Scientific). Native GFP fluorescence in liver and skeletal muscle (quadriceps) was analyzed in 30 μm sections mounted using Permafluor mounting media. All images were captured on a Leica DM5500 B microscope (Leica Microsystems, Buffalo Grove, IL). Postprocessing of images was performed using Adobe Photoshop CS6 (Adobe Systems, San Jose, CA).
Quantification of GFP-positive neurons in striatum and thalamus.
Chromogenic IHC staining of 40 μm mouse brain sections was performed as described in an earlier section. Five 663.28 × 497.40 μm regions were randomly chosen from the striatum or thalamus (n =4 biological replicates per vector) of the stained sections. Neurons were identified by their morphology and counted by individuals blinded to the study design. All statistical analyses were performed using GraphPad Prism (GraphPad Software, La Jolla, CA). Total neurons in the 663.28 × 497.40 μm fields were counted in Nissl (cresyl violet acetate) stained brain sections using ImageJ software. Significance was determined by Student's unpaired two-tailed t-test. A P < 0.05 was considered to be significant.
Biodistribution analysis.
Vector genome copy numbers from various mouse tissues were determined by qPCR after extraction of total DNA using DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). Tissues were mechanically lysed using TissueLyzer II (Qiagen). Vector genome content in each tissue was determined using 100 ng total DNA using the same qPCR method described above for AAV vector titration using a plasmid-based standard curve, and a viral vector internal control for quality assurance. All statistical analyses were performed using GraphPad Prism. Significance was determined by Student's unpaired two-tailed t-test. A P < 0.05 was considered to be significant.
Western blotting to detect GFP protein levels in various tissue types was performed using primary antibodies detecting GFP (chicken polyclonal anti-GFP, 1:2,000, Aves Labs, Tigard, OR, GFP-1010) and mouse β-actin (mouse monoclonal anti-β-actin, 1:1,000, Sigma-Aldrich, A5441), followed by appropriate IRDye secondary antibodies (LI-COR, Lincoln, NE). Total protein was isolated from harvested tissues by bead lysis in T-PER tissue extraction reagent (Life Technologies) and quantified by Bradford assay (Bio-Rad, Hercules, CA). Twenty micrograms of total protein were loaded onto each well of 4-20% Mini-PROTEAN TGX gels (Bio-Rad). Tissues from two representative mice per group were used for analysis. Detection and quantification were done with Odyssey infrared imaging system (LI-COR).
In vitro binding assay. Pro5 and Lec2 CHO cell lines were gifts from Dr. Aravind Asokan (University of North Carolina Chapel Hill) and binding assay was performed as previously described. 46 Briefly, cells were prechilled for 30 minutes at 4 °C in serum-free DMEM (Life Technologies), followed by incubation with rAAV vectors at 4 × 10 4 vg/cell in cold serum-free media DMEM at 4 °C. Ninety minutes later, cells were washed thrice with cold serum-free DMEM to remove loosely bound vector particles. Cells were harvested and total DNA was extracted using DNeasy Blood and Tissue kit (Qiagen). Vector genome copy numbers of cell surface bound virions was quantified by qPCR as described earlier.
In vitro knockdown assay. A 159 bp sequence containing the Htt mRNA target sequence was cloned into pSiCHECK-2 vector (Promega, Madison, WI) between the XhoI and NotI restriction sites in the 3' UTR of the Renilla luciferase gene. Luciferase assays were performed by cotransfection in 24-well plates with 0.025 μg/well of the Htt target-containing pSiCHECK-2 reporter and 0.6 μg/well of GIPZ or AAV transgene plasmid containing either Htt targeting-artificial miRNA sequence (miR Htt ) or scrambled miRNA sequence. Transfections were performed using Lipofectamine 2000 (Invitrogen, Carlsbad, CA), according to the manufacturer's protocol. Fortyeight hours after transfection, the cells were lysed for 20 minutes in 1× passive lysis buffer (Promega). Luciferase activity was read in 96-well plates with the Dual-luciferase assay kit (Promega) using the GloMax multi-detection system (Promega). Renilla luciferase values were normalized for intraplasmid transfection efficacy to firefly luciferase signal. All statistical analyses were performed using GraphPad Prism. Significance was determined by Student's unpaired two-tailed t-test. A P < 0.05 was considered to be significant.
Analysis of in vivo
Htt knockdown. rAAV vectors were administered intravascularly via the tail vein into 6-8-week-old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) at a dose of 9.4 × 10 11 vg/mouse. Mice were euthanized at 4 weeks postinjection and the brain sectioned in 2 mm coronal blocks using a brain matrix. Biopsy punches of different diameters (2 or 3 mm) were used to sample motor cortex (2 mm), striatum (3 mm), and thalamus (3 mm). Cervical spinal cord and liver were also included in the analysis. Tissue samples were mechanically homogenized using a TissueLyzer II and 5 mm stainless steel beads (Qiagen) in Trizol (Life Technologies). Total RNA was isolated using Direct-zol RNA MiniPrep kit (Zymo Research Corporation, Irvine, CA) according to manufacturer's protocol. Total RNA (400-1,000 ng) was reverse transcribed using High Capacity RNA to cDNA kit (Applied Biosystems, Foster City, CA). Relative mouse Htt mRNA expression was assessed by qPCR using TaqMan gene expression assays for mouse Htt (Mm01213820_m1, Applied Biosystems) and hypoxanthine phosphoribosyltransferase 1 (Hprt1; mm00446968_m1, Applied Biosystems). Changes in Htt mRNA for groups injected with AAV9 or AAV-AS vectors were calculated relative to PBS-injected mice using the 2 -ΔΔCT method. 62 Significance was determined by Student's unpaired twotailed t-test. A P < 0.05 was considered to be significant.
For protein analysis, a frozen punch from each region (motor cortex, striatum, thalamus, cervical spinal cord, and liver) was homogenized in 75-300 μl 10 mmol/l HEPES pH7.4, 250 mmol/l sucrose, 1 mmol/l EDTA + protease inhibitor tablet (cOmplete mini, EDTA-free, Roche), 1 mmol/l NaF, and 1 mmol/l Na 3 VO 4 on ice for 30 strokes. Protein concentration was determined by Bradford method (BioRad) and 10 μg motor cortex, striatum, and thalamus or 20 μg cervical spinal cord and liver were loaded onto 3-8% Tris-Acetate gels (Life Technologies) and separated by SDS-PAGE. Proteins were transferred to nitrocellulose using a TransBlot Turbo apparatus (Bio-Rad) then blots were cut horizontally at 72 kD. Blots were washed in TRISbuffered saline + 0.1% Tween 20 (TBST) and blocked in 5% milk/TBST. The top half of the blot was incubated in anti-Htt antibody Ab1 63 (1:2,000) and the bottom half in anti-tubulin antibody (1:4,000, Sigma-Aldrich) or anti-GAPDH antibody (1:6,000, Millipore) diluted in 5% milk/TBST overnight at 4 °C. Blots were washed in TBST then incubated in peroxidase conjugated secondary antibodies diluted in 5% milk/TBST for 1 hour at room temperature, washed, and proteins were detected using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and FluoroChem SP (Alpha Innotech) and Hyperfilm ECL (GE Healthcare). The bottom blots were reprobed with anti-GFP antibody (1:3,000, Cell Signaling Technologies, Danvers, MA). Densitometry was performed using ImageJ software.
ACKNOWLEDGMENTS
The authors thank Brian D'Amore, Erica Mondo, Owen Peters and Lori Kennington for technical assistance, Eric Mick for statistical consultation, and Robert Kotin for critically reading the manuscript. This work was supported by grants R01NS066310 (M.S.-E.) and R01NS38194 (N.A.) from the National Institutes of Health and in part by CHDI Foundation, Inc. G.G. is a founder of Voyager Therapeutics and holds equity in the company. G.G. is an inventor on patents licensed to Voyager Therapeutics. Figure S1 . Biodistribution profile of AAV9.47. Figure S2 . Transduction profile of AAV-AS and AAV9 vectors across multiple CNS regions after systemic delivery. Figure S3 . Biodistribution profile of AAV9.47, AAV9 and AAV-AS vectors in lung, pancreas and kidney. Figure S4 . Assessment of gliosis markers in brain upon AAV infusion. Figure S5 . Cell binding studies of native and peptide-modified AAV vector. Figure S6 . In vitro assessment of knockdown efficiency of miRHtt construct.
SUPPLEMENTARY MATERIAL
